We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas.
- Authors
Hsu, Cheng-Ming; Yang, Ming-Yu; Tsai, Ming-Shao; Chang, Geng-He; Yang, Yao-Hsu; Tsai, Yao-Te; Wu, Ching-Yuan; Chang, Shun-Fu
- Abstract
Head and neck squamous cell carcinomas (HNSCCs) are the most common cancers of the head and neck, and their prevalence is rapidly increasing. HNSCCs present a clinical challenge because of their high recurrence rate, therapeutic resistance to radiation and chemotherapy drugs, and adverse effects. Hence, traditional Chinese herbal treatment may be advantageous to therapeutic strategies for HNSCCs. Danshen (Salvia miltiorrhiza), a well-known Chinese herb, has been extensively applied in treatments for various diseases, including cancer, because of its high degree of safety and low rate of adverse effects despite its unclear mechanism. Thus, we aimed to explore the possible anticancer effects and mechanisms of dihydroisotanshinone I (DT), a compound in danshen (extract from danshen), on HNSCCs. Three HNSCCs cell lines were used for in vitro studies, and a Detroit 562 xenograft mouse model was chosen for in vivo studies. Our in vitro results showed that DT could initiate apoptosis, resulting in cell death, and the p38 signaling partially regulated DT-initiated cell apoptosis in the Detroit 562 model. In the xenograft mouse model, DT reduced tumor size with no obvious adverse effect of hepatotoxicity. The present study suggests that DT is a promising novel candidate for anti-HNSCCs therapy.
- Subjects
SQUAMOUS cell carcinoma; NECK; HEAD &; neck cancer; DRUG resistance; LABORATORY mice; SALVIA miltiorrhiza; THERAPEUTICS
- Publication
International Journal of Molecular Sciences, 2021, Vol 22, Issue 16, p8881
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms22168881